YOL079W Antibody

What is YOL079W and why is it significant in yeast research?

YOL079W is a protein found in Saccharomyces cerevisiae (Baker's yeast), specifically in strain ATCC 204508 / S288c, with UniProt accession number Q08238 . While the specific function of YOL079W is not detailed in the available literature, antibodies against yeast proteins like YOL079W serve as essential tools in fundamental research. These antibodies enable researchers to track protein expression, localization, and interactions within yeast cells, which serve as model organisms for understanding conserved eukaryotic cellular processes. The study of yeast proteins through antibody-based detection methods contributes significantly to our understanding of fundamental biological mechanisms that have parallels in higher organisms, including humans. Yeast models are particularly valuable due to their genetic tractability, rapid growth, and the extensive conservation of basic cellular machinery across eukaryotes.

What are the key specifications of commercially available YOL079W antibodies?

Based on the available information, researchers can access a polyclonal YOL079W antibody (product code CSB-PA902866XA01SVG) with the following specifications :

• Host/Isotype: Rabbit IgG

• Clonality: Polyclonal

• Immunogen: Recombinant Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YOL079W protein

• Validated Applications: ELISA and Western blot (WB)

• Physical Form: Liquid

• Storage Buffer: 50% Glycerol, 0.01M PBS (pH 7.4), with 0.03% Proclin 300 as preservative

• Purification Method: Antigen affinity purified

• Species Reactivity: Saccharomyces cerevisiae (strain ATCC 204508 / S288c)

• Lead Time: Made-to-order (14-16 weeks)

This polyclonal antibody offers advantages in certain experimental contexts, as "polyclonal antibodies are usually more capable of detecting both native and denatured protein variants" , making them versatile across different experimental conditions.

How do polyclonal and monoclonal antibodies differ in yeast protein research applications?

Understanding the differences between polyclonal and monoclonal antibodies is crucial for experimental design in yeast research:

What are the optimal experimental conditions for Western blotting with YOL079W antibodies?

Western blotting with YOL079W antibodies requires careful optimization to achieve reliable and reproducible results. The following protocol has been optimized based on general principles of yeast protein detection:

Sample Preparation:

• Culture yeast to mid-log phase (OD₆₀₀ = 0.6-0.8)

• Harvest cells by centrifugation (3,000 g, 5 min)

• Resuspend in lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1 mM EDTA, protease inhibitors)

• Add acid-washed glass beads and vortex 8×30 seconds with cooling on ice between cycles

• Centrifuge at 10,000 g for 15 minutes to clear cell debris

• Quantify protein concentration by Bradford or BCA assay

SDS-PAGE and Transfer:

• Load 20-50 μg total protein per lane

• Separate on 10-12% polyacrylamide gel

• Transfer to PVDF membrane (0.45 μm) at 100V for 1 hour or 30V overnight at 4°C

• Verify transfer efficiency with reversible protein stain

Antibody Incubation and Detection:

• Block membrane with 5% non-fat milk in TBST for 1 hour at room temperature

• Incubate with YOL079W antibody (1:1000 dilution) overnight at 4°C

• Wash 3×10 minutes with TBST

• Incubate with HRP-conjugated anti-rabbit secondary antibody (1:5000) for 1 hour

• Wash 3×10 minutes with TBST

• Develop using enhanced chemiluminescence substrate

• Image using appropriate detection system

Optimization Parameters:

• Antibody Dilution: Titrate from 1:500 to 1:2000 to determine optimal signal-to-noise ratio

• Blocking Agent: Compare 5% milk vs. 3-5% BSA if background is problematic

• Incubation Time: Adjust primary antibody incubation (2 hours RT vs. overnight 4°C)

• Washing Stringency: Increase wash duration or detergent concentration if background persists

Remember that "while in some applications (i.e. Western blot) denatured protein must be detected, other applications require the detection of native GFP. Polyclonal antibodies are usually more capable of detecting both variants" , which applies conceptually to YOL079W detection as well.

How should researchers prepare yeast samples for optimal YOL079W detection?

The detection of YOL079W in yeast samples requires optimized extraction methods to preserve protein integrity while ensuring efficient extraction:

Comparative Analysis of Extraction Methods:

Optimized Protocol for YOL079W Extraction:

• Growth and Harvesting:

  • Culture yeast in appropriate medium to mid-log phase

  • Harvest by centrifugation (3,000 g, 5 minutes)

  • Wash cell pellet with ice-cold water

• Lysis Buffer Selection:

  • For denatured applications: 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 5 mM EDTA, 1 mM PMSF, protease inhibitor cocktail

  • For native applications: 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1-0.5% NP-40, 10% glycerol, 1 mM EDTA, protease inhibitors

• Mechanical Disruption:

  • Resuspend cells in lysis buffer (1:1 ratio of cell pellet to buffer)

  • Add acid-washed glass beads (0.5 mm) to 50% of total volume

  • Vortex 8 times for 30 seconds with 30-second cooling intervals on ice

  • Monitor lysis progress microscopically (>80% cell disruption is optimal)

• Extract Processing:

  • Centrifuge at low speed (1,000 g, 5 minutes) to remove unbroken cells and debris

  • Transfer supernatant to fresh tube and centrifuge at high speed (15,000 g, 15 minutes) to clarify

  • For membrane proteins, ultracentrifuge at 100,000 g for 1 hour

  • Quantify protein concentration using Bradford or BCA assay

• Sample Storage:

  • Aliquot samples to avoid freeze-thaw cycles

  • Add glycerol to 10% final concentration for cryoprotection

  • Flash-freeze in liquid nitrogen and store at -80°C

These methods provide comprehensive approaches to yeast sample preparation, ensuring that researchers can effectively detect YOL079W while preserving its native characteristics and interactions for various experimental applications.

What controls are essential for validating YOL079W antibody specificity?

Rigorous validation of antibody specificity is critical for ensuring reliable research outcomes. For YOL079W antibodies, implement the following comprehensive validation strategy:

Essential Controls for YOL079W Antibody Validation:

• Genetic Controls:

  • YOL079W knockout/deletion strain (Δyol079w)

  • Wild-type strain as positive control

  • YOL079W overexpression strain

  • Tagged YOL079W strain (e.g., YOL079W-GFP or YOL079W-TAP tag)

• Technical Controls:

  • Primary antibody omission control

  • Isotype control (non-specific rabbit IgG at equivalent concentration)

  • Secondary antibody only control

  • Loading control antibody (e.g., anti-actin or anti-GAPDH)

• Biochemical Controls:

  • Peptide competition assay (pre-incubate antibody with immunizing peptide)

  • Sequential dilution series of target protein

  • Orthogonal detection method (e.g., mass spectrometry of immunoprecipitated material)

Validation Protocol for Peptide Competition Assay:

• Divide antibody solution into two equal aliquots

• Add immunizing peptide (5-10× molar excess) to one aliquot

• Add equivalent volume of buffer to the other aliquot

• Incubate both at 4°C for 2 hours with gentle rotation

• Use both solutions in parallel Western blots with identical samples

• Compare signal - specific bands should be significantly reduced or eliminated in the peptide-competition lane

Validation Decision Matrix:

How can YOL079W antibodies be optimized for immunoprecipitation of protein complexes?

Immunoprecipitation (IP) of YOL079W to study protein complexes requires specific optimization strategies to maintain native interactions while ensuring efficient pulldown:

Optimized IP Protocol for YOL079W Protein Complexes:

• Preparation Phase:

  • Culture yeast to mid-log phase in 100-200 mL of appropriate medium

  • Harvest cells (3,000 g, 5 minutes, 4°C)

  • Wash twice with ice-cold PBS

• Gentle Lysis for Complex Preservation:

  • Resuspend cells in IP lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% NP-40, 10% glycerol, 1 mM EDTA, protease inhibitors, phosphatase inhibitors)

  • Use glass bead lysis with gentle vortexing (6×30 seconds with 2-minute cooling intervals)

  • Clear lysate by centrifugation (15,000 g, 15 minutes, 4°C)

• Pre-clearing Step:

  • Incubate lysate with 50 μL Protein A or G beads for 1 hour at 4°C

  • Remove beads by centrifugation (1,000 g, 2 minutes)

• Immunoprecipitation:

  • For direct IP: Add 5 μg YOL079W antibody to 1 mg pre-cleared lysate

  • For cross-linked approach: First cross-link antibody to beads using dimethyl pimelimidate

  • Incubate overnight at 4°C with gentle rotation

  • Add 50 μL Protein A beads (for rabbit polyclonal antibody)

  • Incubate 2-3 hours at 4°C with gentle rotation

• Washing and Elution Strategy:

  • Wash beads 4× with IP buffer containing decreasing detergent concentrations

  • For interacting protein analysis: Elute with SDS sample buffer (95°C, 5 minutes)

  • For native complex analysis: Elute with excess immunizing peptide or low pH glycine buffer

Optimization Parameters for Complex Preservation:

Analysis of Immunoprecipitated Complexes:

• Western Blotting: Probe for suspected interaction partners

• Mass Spectrometry: Identify all co-precipitated proteins

• Activity Assays: Measure enzymatic activity of purified complexes

• Structural Analysis: Analyze complex architecture by negative stain EM

When designing IP experiments with YOL079W antibodies, consider that "antibodies from different host species can be advantageous in multiplex experiments" , which may be relevant for sequential or comparative IPs of different yeast proteins.

What strategies can address weak or inconsistent YOL079W antibody signals?

Researchers encountering weak or inconsistent signals when using YOL079W antibodies can implement several optimization strategies:

Systematic Troubleshooting Approach:

• Antibody-Related Optimization:

  • Titrate antibody concentration (try 1:500, 1:1000, 1:2000 dilutions)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Test different antibody lots if available

  • Consider alternative antibody if persistent issues occur

• Sample Preparation Enhancement:

  • Increase protein loading (50-100 μg per lane)

  • Try protein enrichment methods (immunoprecipitation before Western)

  • Use protein concentration methods (TCA precipitation)

  • Prepare fresh lysates to minimize degradation

• Detection System Improvement:

  • Use high-sensitivity ECL substrate for chemiluminescence

  • Try fluorescent secondary antibodies for greater linear range

  • Optimize exposure times and imaging parameters

  • Consider amplification systems (biotinylated secondary + streptavidin-HRP)

Decision Tree for Signal Optimization:

Advanced Signal Enhancement Protocol:

• Epitope Retrieval: For fixed samples, try heat-induced epitope retrieval (HIER) or enzymatic retrieval

• Signal Amplification: Implement tyramide signal amplification (TSA) for immunofluorescence

• Sensitivity Boosting: Use polymer-HRP detection systems instead of traditional secondary antibodies

• Background Reduction: Add 0.1-0.5% non-ionic detergent to antibody dilution buffer

"While in some applications (i.e. Western blot) denatured protein must be detected, other applications require the detection of native [protein]. Polyclonal antibodies are usually more capable of detecting both variants" . This principle applies to YOL079W detection as well, so consider the native/denatured state of your target in troubleshooting.

How can computational approaches enhance YOL079W antibody experimental design?

Modern computational approaches can significantly improve antibody-based experimental design for YOL079W research:

Computational Tools for Enhancing YOL079W Antibody Experiments:

• Epitope Prediction and Analysis:

  • Use protein structure prediction (AlphaFold, RoseTTAFold) to model YOL079W

  • Identify surface-exposed, unique regions for targeted detection

  • Predict potential cross-reactive epitopes in related proteins

  • Design experiments targeting specific domains or structural features

• Cross-Reactivity Assessment:

  • Perform in silico analysis of sequence similarity with other yeast proteins

  • Identify potential off-targets that share epitope sequences

  • Design controls to specifically test predicted cross-reactivity

  • Implement "biophysics-informed model[s]... to disentangle the different contributions to binding"

• Experimental Optimization Modeling:

  • Simulate antibody binding under different buffer conditions

  • Predict optimal antibody concentrations based on affinity modeling

  • Design experimental workflows with maximum statistical power

  • Model epitope accessibility in different experimental conditions

Implementation Framework for Computational Enhancement:

Advanced Application - Computational Antibody Improvement:
Recent research has demonstrated that computational approaches can "identify just a few key amino-acid substitutions necessary to restore the antibody's potency" . Similar approaches could be adapted to optimize YOL079W antibodies by:

• Modeling the antibody-antigen interface

• Identifying key binding residues

• Predicting modifications to enhance specificity or affinity

• Designing validation experiments to test computational predictions

These computational approaches represent "a promising strategy to recover antibody functionality and avoid the time-consuming process of discovering entirely new antibodies" , which can be particularly valuable when working with challenging targets like yeast proteins.

How can YOL079W antibodies be utilized in protein-protein interaction studies?

YOL079W antibodies can serve as powerful tools for investigating protein-protein interactions in yeast through several methodological approaches:

Co-Immunoprecipitation (Co-IP) Protocol:

• Prepare native yeast lysate in mild lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% NP-40, 1 mM EDTA, protease inhibitors)

• Pre-clear lysate with Protein A beads (1 hour, 4°C)

• Incubate 1-2 mg pre-cleared lysate with 5 μg YOL079W antibody overnight at 4°C

• Add 50 μL Protein A beads and incubate 2-3 hours at 4°C

• Wash beads 4× with lysis buffer

• Elute bound proteins with SDS sample buffer

• Analyze by SDS-PAGE and immunoblotting for suspected interaction partners or mass spectrometry for unbiased discovery

Proximity-Based Interaction Methods:

• Proximity Ligation Assay (PLA):

  • Fix and permeabilize yeast cells

  • Incubate with YOL079W antibody and antibody against potential interactor

  • Add PLA probes (secondary antibodies with DNA oligonucleotides)

  • Perform ligation and rolling circle amplification

  • Visualize amplified signal by fluorescence microscopy

• BioID/TurboID Combined with Antibody Detection:

  • Generate YOL079W-BioID fusion protein in yeast

  • Induce biotinylation of proximal proteins

  • Perform streptavidin pulldown of biotinylated proteins

  • Validate identified interactions using YOL079W antibody in reverse Co-IP

Comparative Analysis of YOL079W Interaction Detection Methods:

Data Validation and Quality Control:

• Perform reciprocal IPs when antibodies to interaction partners are available

• Include non-specific IgG control and genetic controls (deletion strains)

• Quantify enrichment relative to input and IgG control

• Verify key interactions with orthogonal methods

These approaches can be enhanced using concepts from antibody engineering research where "biophysically interpretable model[s]" can help "disentangle the different contributions to binding" , which is particularly valuable when studying complex protein interaction networks.

What methods can integrate YOL079W antibody detection with functional genomics approaches?

Integrating YOL079W antibody-based detection with functional genomics creates powerful research paradigms for comprehensive protein characterization:

Integrated Methodological Approaches:

• ChIP-Seq Integration:

  • Use YOL079W antibody for chromatin immunoprecipitation

  • Sequence DNA associated with YOL079W protein

  • Correlate binding sites with gene expression data

  • Map genome-wide binding patterns and regulatory networks

• Proteomics-Transcriptomics Correlation:

  • Quantify YOL079W protein levels using antibody-based methods

  • Pair with RNA-seq data from the same samples

  • Analyze protein-mRNA correlation across conditions

  • Identify post-transcriptional regulatory mechanisms

• Genetic Interaction Mapping:

  • Apply YOL079W antibody detection in genetic perturbation screens

  • Measure protein level changes across mutant libraries

  • Correlate protein abundance with phenotypic outcomes

  • Identify genetic interactions affecting YOL079W function

• Spatiotemporal Analysis:

  • Use immunofluorescence with YOL079W antibody across cell cycle stages

  • Combine with live-cell imaging of tagged interaction partners

  • Create time-resolved maps of protein localization and dynamics

  • Correlate with functional data from synchronized populations

Implementation Framework for Multi-omics Integration:

Advanced Analysis Protocol - ChIP-Proteomics Integration:

• Perform ChIP with YOL079W antibody under conditions of interest

• Split sample for:

  • DNA sequencing (identify binding sites)

  • Proteomic analysis (identify co-bound proteins)

• Integrate datasets to identify:

  • Genomic regions where YOL079W and specific partners co-localize

  • Condition-specific binding patterns and complex compositions

• Validate key findings with targeted ChIP-qPCR and Co-IP experiments

This integrated approach draws conceptually from advanced antibody research where "biophysics-informed modeling and extensive selection experiments" enable deeper insights into complex biological systems, applying similar principles to functional genomics integration with antibody-based detection.

How can researchers evaluate post-translational modifications of YOL079W using antibody-based approaches?

Post-translational modifications (PTMs) of YOL079W can be studied using sophisticated antibody-based approaches combined with other analytical techniques:

Methodological Approaches for PTM Analysis:

• Phosphorylation Analysis:

  • Immunoprecipitate YOL079W using specific antibody

  • Analyze by:

    • Western blot with phospho-specific antibodies (if available)

    • Phos-tag SDS-PAGE to separate phosphorylated forms

    • Mass spectrometry for site identification

  • Validate with phosphatase treatment controls

  • Map kinase-substrate relationships using inhibitors

• Ubiquitination Detection:

  • Perform denaturing IP to preserve ubiquitin linkages:

    • Lyse cells in 1% SDS, boil, dilute to 0.1% SDS

    • Immunoprecipitate with YOL079W antibody

  • Detect ubiquitination by Western blot with anti-ubiquitin antibody

  • Confirm with proteasome inhibitor treatments

  • Identify E3 ligases through candidate approach or siRNA screening

• SUMOylation and Other Modifications:

  • Use tandem affinity purification:

    • His-tagged SUMO and YOL079W antibody

    • Sequential purification under denaturing conditions

  • Analyze by Western blot and mass spectrometry

  • Create modification-specific mutants for functional validation

Comparative Analysis of PTM Detection Methods:

Protocol for Integrated PTM Analysis:

• Sample Preparation:

  • Treat yeast with PTM-preserving conditions (phosphatase inhibitors, HDAC inhibitors, proteasome inhibitors)

  • Lyse in denaturing conditions (8M urea or 1% SDS with heating)

  • Dilute for immunoprecipitation with YOL079W antibody

• Multi-level Analysis:

  • First level: Western blot with modification-specific antibodies

  • Second level: Specialized electrophoresis (Phos-tag, SUMO-tag)

  • Third level: IP-MS with PTM-specific enrichment strategies

• Functional Validation:

  • Generate site-specific mutants (phospho-mimetic, phospho-null)

  • Assess functional consequences of mutations

  • Monitor modification dynamics during cellular processes

These approaches leverage concepts from antibody engineering where "disentangling the different contributions" to signals is critical, particularly when analyzing complex patterns of post-translational modifications that may coexist on the same protein.

What are the current limitations in YOL079W antibody research and emerging solutions?

Current YOL079W antibody research faces several limitations that researchers should consider, along with emerging solutions to address these challenges:

Technical Limitations and Solutions:

The scientific community is addressing these limitations through several innovative approaches:

• Computationally Designed Antibodies:
  Recent advances demonstrate that "computational redesign [is] a promising strategy to recover antibody functionality and avoid the time-consuming process of discovering entirely new antibodies" . These approaches can be adapted to develop improved YOL079W antibodies with enhanced specificity and sensitivity.

• Advanced Validation Standards:
  More rigorous validation using multiple orthogonal techniques ensures that "binding modes associated with specific ligands" are properly characterized, improving confidence in experimental results.

• Integrated Multi-omics Approaches:
  Combining antibody-based detection with orthogonal methods provides more comprehensive insights while mitigating the limitations of any single approach.

• Machine Learning for Experiment Optimization:
  Computational approaches using "biophysics-informed models to identify and disentangle multiple binding modes" can optimize experimental conditions for specific applications.

• Recombinant Antibody Technologies:
  Transitioning from animal-derived polyclonal antibodies to recombinant monoclonal antibodies ensures greater reproducibility and consistent performance across experiments.

These emerging solutions promise to enhance the reliability, specificity, and applicability of YOL079W antibodies in fundamental yeast research, enabling more sophisticated studies of protein function, interaction, and regulation.

How can researchers integrate multiple detection methods to enhance YOL079W characterization?

Comprehensive characterization of YOL079W benefits from integrating multiple detection methods to overcome the limitations of individual approaches:

Multi-modal Detection Strategy:

• Primary Detection with YOL079W Antibody:

  • Western blotting for expression level quantification

  • Immunofluorescence for subcellular localization

  • Immunoprecipitation for interaction partners

• Complementary Genetic Approaches:

  • YOL079W-GFP/RFP fusion for live-cell imaging

  • TAP-tagged YOL079W for tandem affinity purification

  • CRISPR-based endogenous tagging for physiological expression

• Mass Spectrometry Integration:

  • Analysis of immunoprecipitated material

  • Targeted MS for specific PTM detection

  • Global proteomics for expression correlation

• Functional Assays:

  • Phenotypic analysis of deletion/overexpression strains

  • Condition-specific growth and stress response

  • Activity assays if enzymatic function is known

Integration Framework and Data Correlation:

Implementation Protocol - Multi-level Validation:

• Level 1: Expression Analysis

  • Quantify YOL079W levels by Western blot across conditions

  • Validate with targeted MS using isotope-labeled standards

  • Correlate with mRNA levels from RNA-seq

• Level 2: Localization Studies

  • Map subcellular distribution using immunofluorescence

  • Confirm with live-cell imaging of tagged variants

  • Track dynamic changes during cellular processes

• Level 3: Interaction Analysis

  • Identify interactors by antibody-based Co-IP

  • Validate key interactions with reverse Co-IP

  • Map interaction interfaces using truncation mutants

• Level 4: Functional Studies

  • Correlate protein levels with phenotypic outcomes

  • Manipulate YOL079W activity (genetic or chemical approaches)

  • Assess impact on cellular pathways and processes

This integrated approach draws conceptually from computational antibody engineering research where "the model successfully disentangles [different] modes, even when they are associated with chemically very similar ligands" , applying similar principles to disentangle complex biological signals from multiple detection methods.